Annis Gardner Whiting Capital Advisors LLC Takes Position in Iovance Biotherapeutics, Inc. $IOVA

Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 100,400 shares of the biotechnology company’s stock, valued at approximately $352,000.

Several other large investors also recently modified their holdings of IOVA. Ceera Investments LLC bought a new stake in shares of Iovance Biotherapeutics in the first quarter worth about $44,000. Sanctuary Advisors LLC bought a new position in Iovance Biotherapeutics during the 1st quarter valued at approximately $38,000. Chicago Partners Investment Group LLC raised its position in Iovance Biotherapeutics by 29.7% during the 1st quarter. Chicago Partners Investment Group LLC now owns 52,653 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 12,064 shares during the last quarter. Fifth Third Bancorp purchased a new stake in Iovance Biotherapeutics in the 1st quarter worth approximately $39,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in Iovance Biotherapeutics in the 1st quarter worth approximately $110,000. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Trading Up 7.3%

IOVA opened at $5.00 on Friday. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -5.26 and a beta of 0.70. The stock has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $3.55. Iovance Biotherapeutics, Inc. has a 12-month low of $1.76 and a 12-month high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, meeting analysts’ consensus estimates of ($0.19). The firm had revenue of $71.43 million for the quarter, compared to analysts’ expectations of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The company’s quarterly revenue was up 44.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.36) EPS. On average, analysts predict that Iovance Biotherapeutics, Inc. will post -0.62 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IOVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Chardan Capital decreased their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Truist Financial raised Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.43.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.